Tesla
TSLA
NVIDIA
NVDA
Palantir
PLTR
4
Taiwan Semiconductor
TSM
5
Apple
AAPL
US Stock MarketDetailed Quotes
CAPR Capricor Therapeutics
- 12.340
- -0.470-3.67%
Close Mar 10 16:00 ET
- 12.910
- +0.570+4.62%
Post 20:01 ET
561.10MMarket Cap-12.10P/E (TTM)
12.834High12.000Low1.62MVolume12.690Open12.810Pre Close19.85MTurnover4.06%Turnover RatioLossP/E (Static)45.47MShares23.40052wk High8.22P/B492.85MFloat Cap3.52052wk Low--Dividend TTM39.94MShs Float7999.998Historical High--Div YieldTTM6.51%Amplitude0.880Historical Low12.239Avg Price1Lot Size
Capricor Therapeutics Stock Forum
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
First-Ever DMD Cardiomyopathy Treatment Advances: FDA Fast-Tracks Capricor's Groundbreaking Therapy
Capricor Therapeutics Announces FDA Acceptance and Priority Review of Its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
GlobeNewswire· 22 mins ago11mins
Capricor Therapeutics(CAPR.US)
--FDA assigns PDUFA target action date of August 31, 2025--
--If approved, deramiocel would be first therapy to treat Duchenne muscular dystrophy cardiomyopathy--
--At this time, FDA has not identified any potential review issues with the BLA-...
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
will close above 21 today....
No comment yet